middle.news
How Is Chimeric Therapeutics Turning Clinical Progress Into Financial Stability?
4:55pm on Friday 29th of August, 2025 AEST
•
Biotechnology
Read Story
How Is Chimeric Therapeutics Turning Clinical Progress Into Financial Stability?
4:55pm on Friday 29th of August, 2025 AEST
Key Points
FY2025 loss narrowed to $10.43 million from $12.53 million
Clinical advancement in CDH17 CAR T-cell and CORE-NK natural killer cell therapies
Secured US patent protection for CDH17 CAR construct through 2039
Raised over $11 million via placements plus $4 million philanthropic funding
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE